Based on the predicted therapeutic targets and active compounds of AGS, we performed a molecular docking analysis for 6 active components and 5 collective targets to provide a rational explanation for the anti-CRC effect of AGS, and the results showed that AGS had a strong docking capability with SRC and ESR1. The gene discussed is JAG1; the disease is colorectal carcinoma.